Metacam 2.5 mg Chewable Tablets (Canada)This page contains information on Metacam 2.5 mg Chewable Tablets for veterinary use.
The information provided typically includes the following:
- Metacam 2.5 mg Chewable Tablets Indications
- Warnings and cautions for Metacam 2.5 mg Chewable Tablets
- Direction and dosage information for Metacam 2.5 mg Chewable Tablets
Metacam 2.5 mg Chewable TabletsThis treatment applies to the following species:
1.0 mg chewable tablets for dogs DIN 02318997
2.5 mg chewable tablets for dogs DIN 02319004
Veterinary Use Only
Metacam 2.5 mg Chewable Tablets Indications
Metacam® is a nonsteroidal anti-inflammatory drug (NSAID) of the oxicam group for use in dogs. It acts by inhibition of prostaglandin synthesis and is indicated for the alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders.
Dosage and AdministrationInitial treatment is a single dose of 0.2 mg meloxicam/kg body weight on the first day, which can be given orally or alternatively using Metacam® 5 mg/mL solution for injection.
Treatment is to be continued once daily by oral administration (at 24-hour intervals) at a maintenance dose of 0.1 mg meloxicam/kg body weight. Each chewable tablet contains either 1.0 mg or 2.5 mg meloxicam, which corresponds to the daily maintenance dose for a 10 kg body weight dog, or a 25 kg body weight dog respectively. Tablets are scored and dosage should be calculated in half-tablet increments. Improvement is normally seen within 3-4 days. Treatment should be discontinued after 10 days at the latest if no improvement is apparent.
Palatability: A controlled palatability study demonstrated free choice acceptance of 98.2% for the 1 mg chewable tablet, and of 99.5% for the 2.5 mg chewable tablet; the placebo was a treat type dog biscuit and had an acceptance of 100%.
Metacam® should not be administered if gastric or intestinal ulceration or bleeding is suspected; if there is evidence of cardiac, hepatic or renal disease; or if there is evidence of a haemorrhagic disorder or individual hypersensitivity to the product. Do not administer concurrently, other steroidal or nonsteroidal anti-inflammatory drugs (NSAIDs), aminoglycoside antibiotics or anti-coagulant agents. Pre-treatment with other steroidal or nonsteroidal anti-inflammatory drugs (NSAIDs) may result in additional or increased effects and accordingly a treatment-free period with such drugs should be observed for at least 24 hours before commencement of treatment depending on the pharmacokinetic properties of the products used previously.
Metacam 2.5 mg Chewable Tablets Caution
Not approved for use in cats. Metacam® should not be administered to breeding, pregnant or lactating dogs. Do not exceed the stated dose. In case of overdosing, symptomatic treatment should be initiated. Animals being treated with meloxicam should be monitored for the occurrence of side effects as susceptibility varies with the individual. Adverse reactions reported with the NSAID class of drugs include gastrointestinal signs, renal and hepatic toxicity as well as hematological, neurological and dermatological abnormalities.
If gastrointestinal or other side effects occur, treatment should be discontinued.
As for all NSAIDs, use in any animal less than 6 weeks of age or in debilitated aged animals may involve additional risk. To optimize dosing accuracy in higher risk patients, it is recommended that consideration be given to prescribe Metacam® Oral Suspension (DIN 02237715), a formulation that allows for more accurate body weight dosing, in animals less than 6 weeks of age and/or less than 5 kg body weight and/or in debilitated aged animals and/or in patients at greatest risk for gastrointestinal and/or renal toxicity. If use of Metacam Chewable Tablets in such animals cannot be avoided, a reduced dosage and careful clinical management may be required.
Warning: Keep out of reach of children.
Adverse Effects: The safety profile of meloxicam has been evaluated in well controlled target animal safety studies in the dog. Dogs treated with placebo, 1X, 3X and 5X label dosages were closely monitored over a 180 day (26 weeks) period. The study determined that there were no drug related adverse effects on clinical observations, normal body weight gain, food consumption, physical and ophthalmic examinations, clotting times, mucosal bleeding times or on a panel of clinical pathology parameters monitored throughout the study.
Postmarketing reports of suspected adverse drug reactions (SADRs) following field use of Metacam® (meloxicam) have been monitored worldwide since 1995.
Based on case reports received under a voluntary reporting system by veterinarians or pet owners/caregivers, the most important affected body system was the gastrointestinal tract followed in decreasing order by central nervous system/behavioural signs, renal and dermatological system. Case reports often did not provide sufficient information to establish cause of the signs observed. In most cases, adverse effects were transient and disappeared after termination of treatment. In rare cases however, death has been associated with some of these adverse reactions. The following suspected adverse effects have been reported:
Gastrointestinal: Vomiting, diarrhea, inappetence, melena, hematemesis, ulceration.
Central Nervous System/Behavioural: Ataxia, personality change, seizures, sleepiness, hyperactivity, depression, trembling.
Renal: Elevated creatinine and BUN, acute renal failure.
Dermatologic: Pruritus, eczema, focal alopecia, moist dermatitis (hot spots).
Hypersensitivity: Urticaria, allergic dermatitis.
Hematologic: Immune mediated hemolytic anemia, immune mediated thrombocytopenia.
Hepatic: Elevated liver enzymes, jaundice.
Information for Pet Owners: Metacam® (meloxicam) is a nonsteroidal anti-inflammatory drug (NSAID) and as with others in this group, side effects may occur in treated dogs. The most common adverse effects reported involve the gastrointestinal tract and usually occur within the first week of treatment. Typical symptoms include loss of appetite, vomiting, diarrhea, dark stools and depression. It is important in these situations to discontinue treatment and contact your veterinarian. In most cases, the side effects are transient and disappear after termination of treatment but in rare instances may be serious. Dogs undergoing prolonged treatment with Metacam® should be monitored periodically. Consult your veterinarian.
StorageStore at 15-25°C. Store in the original package. Protect from moisture.
Boehringer Ingelheim (Canada) Ltd., 5180 South Service Road, Burlington, Ontario L7L 5H4
Presentation: Cartons of 84 tablets per blister pack.
NAC No.: 1230064.2
5180 SOUTH SERVICE ROAD, BURLINGTON, ON, L7L 5H4
|Customer Care No.:||800-567-1885|
|Technical Services No.:||1-877-565-5501|
|Every effort has been made to ensure the accuracy of the Metacam 2.5 mg Chewable Tablets information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the Canadian product label or package insert.|
Copyright © 2017 North American Compendiums. Updated: 2017-11-28